WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2005063981) MUTANTS OF ANTI-CD40 ANTIBODY
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/063981    International Application No.:    PCT/JP2004/019750
Publication Date: 14.07.2005 International Filing Date: 24.12.2004
IPC:
C07K 16/28 (2006.01)
Applicants: KIRIN BEER KABUSHIKI KAISHA [JP/JP]; 10-1, Shinkawa 2-chome Chuo-ku, Tokyo 1048288 (JP) (For All Designated States Except US).
TAKAHASHI, Nobuaki [JP/JP]; (JP) (For US Only).
MIURA, Toru [JP/JP]; (JP) (For US Only).
KITAGAWA, Yoshinori [JP/JP]; (JP) (For US Only).
HIRANO, Aki [JP/JP]; (JP) (For US Only)
Inventors: TAKAHASHI, Nobuaki; (JP).
MIURA, Toru; (JP).
KITAGAWA, Yoshinori; (JP).
HIRANO, Aki; (JP)
Agent: HIRAKI, Yusuke; Kamiya-cho MT Bldg. 19F 3-20, Toranomon 4-chome Minato-ku, Tokyo 1050001 (JP)
Priority Data:
2003-431408 25.12.2003 JP
Title (EN) MUTANTS OF ANTI-CD40 ANTIBODY
(FR) MUTANTS D'UN ANTICORPS ANTI-CD40
(JA) 抗CD40抗体の変異体
Abstract: front page image
(EN)It is intended to provide mutants of anti-CD40 antibody, which is expected as therapeutically efficacious, having been optimized as a drug by lowering the ADCC and CDC activities thereof. Namely, an agonistic anti-CD40 monoclonal antibody mutant in which at least the hinge region is a hinge region originating in human IgG2 and which has a mutation and/or a substitution of one or more amino acids causing lowering in the ADCC and/or CDC activities in the constant region; and an antagonistic anti-CD40 antibody mutant which has at least one mutation and/or substitution causing lowering in the ADCC and/or CDC activities in the constant region.
(FR)L'invention concerne des mutants d'un anticorps anti-CD40, dont on attend une efficacité thérapeutique, après optimisation comme médicament par abaissement des activités ADCC et CDC. L'invention concerne notamment un mutant agoniste de l'anticorps monoclonal anti-CD40, ce mutant ayant au moins la région charnière originaire du IgG2 humain et présentant une mutation et/ou une substitution d'un ou de plusieurs aminoacides provoquant l'abaissement des activités ADCC et/ou CDC dans la région constante. La présente invention porte également sur un mutant antagoniste de l'anticorps anti-CD40, présentant au moins une mutation et/ou une substitution provoquant l'abaissement des activités ADCC et/ou CDC dans la région constante.
(JA) 治療効果が期待できる抗CD40抗体について、医薬品としての最適化の図られたADCC活性およびCDC活性が低減された変異体の提供。 少なくともヒンジ領域がヒトIgG2に由来するヒンジ領域であり、定常領域にADCCおよび/またはCDC活性の低減をもたらす1アミノ酸以上の変異および/または置換を含む、アゴニスティック抗CD40モノクローナル抗体の変異体および定常領域にADCCおよび/またはCDC活性の低減をもたらす1以上の変異もしくは置換を含むアンタゴニスティック抗CD40抗体の変異体。
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)